Terminated PHASE2 INTERVENTIONAL 2-arm NCT05355597

The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors

Sponsor: Atlantic Health System

Conditions Musculoskeletal Diseases Soft Tissue Mass

Interventions Exparel Injectable Product Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)

Updated 5 times since 2022 Last updated: Apr 7, 2025 Started: Jan 27, 2021 Primary completion: Mar 24, 2025 Completion: Mar 24, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Physician left institution

Other terminated trials from Atlantic Health System

See all terminations from Atlantic Health System

Other Musculoskeletal Diseases trials with similar outcome

NCT02367079 · Phase PHASE4 · Apr 2014

Browse all Musculoskeletal Diseases trials

This PHASE2 trial investigates Musculoskeletal Diseases and Soft Tissue Mass and is currently terminated or withdrawn. Atlantic Health System leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

May 2025 — Present [monthly]

Terminated PHASE2

Status: Unknown → Terminated
Sep 2024 — May 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2022 — May 2024 [monthly]

Recruiting PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atlantic Health System

Data source: Atlantic Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Morristown, United States